<SEC-DOCUMENT>0001213900-25-020786.txt : 20250305
<SEC-HEADER>0001213900-25-020786.hdr.sgml : 20250305
<ACCEPTANCE-DATETIME>20250305171033
ACCESSION NUMBER:		0001213900-25-020786
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20250305
FILED AS OF DATE:		20250305
DATE AS OF CHANGE:		20250305

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Scinai Immunotherapeutics Ltd.
		CENTRAL INDEX KEY:			0001611747
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37353
		FILM NUMBER:		25712330

	BUSINESS ADDRESS:	
		STREET 1:		JERUSALEM BIOPARK, 2ND FLOOR
		STREET 2:		HADASSAH EIN KEREM CAMPUS
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			00000
		BUSINESS PHONE:		972-8-9302529

	MAIL ADDRESS:	
		STREET 1:		JERUSALEM BIOPARK, 2ND FLOOR
		STREET 2:		HADASSAH EIN KEREM CAMPUS
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BiondVax Pharmaceuticals Ltd.
		DATE OF NAME CHANGE:	20140624
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>ea0233227-6k_scinai.htm
<DESCRIPTION>REPORT OF FOREIGN PRIVATE ISSUER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>UNITED STATES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 6-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Report of Foreign Private Issuer Pursuant to Rule
13a-16 or 15d-16</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Under the Securities Exchange Act of 1934</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">For the Month of March 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Commission File Number: 001-37353</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SCINAI IMMUNOTHERAPEUTICS LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Translation of registrant&rsquo;s name into English)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Jerusalem BioPark, 2nd Floor</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Hadassah Ein Kerem Campus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Jerusalem, Israel</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive office)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Indicate by check mark whether the registrant files
or will file annual reports under cover Form 20-F or Form 40-F.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Form 20-F &#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Form 40-F &#9744;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Explanatory Note</B>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">On March
5, 2025, Scinai Immunotherapeutics Ltd. issued a press release announcing $10 Million Standby Equity Purchase Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">A copy of
the press release is furnished herewith as Exhibit 99.1.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="background-color: white">This Report
on Form 6-K is hereby incorporated by reference into the registrant&rsquo;s Registration Statements on Form S-8&nbsp;(File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390023030288/ea176534-s8_biondvaxpharma.htm">333-271293</A>&nbsp;and
File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390020015429/ea123060-s8_biondvaxpharma.htm">333-239344</A>)
and&nbsp;Form F-3&nbsp;(File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390023068963/ea183844-f3_biondvaxpharma.htm">333-274078</A>&nbsp;and
File No.&nbsp;<A HREF="http://www.sec.gov/Archives/edgar/data/1611747/000121390024007939/ea192382-f3_scinaiimmun.htm">333-276767</A>),
to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently
filed or furnished.</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit Index</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1.5pt solid; width: 9%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit&nbsp;No.</B></FONT></TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; width: 90%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ea023322701ex99-1_scinai.htm">Press release dated March 5, 2025</A>.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 36pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Scinai Immunotherapeutics Ltd.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 36%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: March 5, 2025</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Amir Reichman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amir Reichman</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea023322701ex99-1_scinai.htm
<DESCRIPTION>PRESS RELEASE DATED MARCH 5, 2025
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><B><BR>
SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT</B></P>

<P STYLE="text-align: left; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">JERUSALEM,&nbsp;March 5, 2025&nbsp;/PRNewswire/ -- Scinai Immunotherapeutics
Ltd. (Nasdaq: SCNI) (&ldquo;Scinai&rdquo; or the &ldquo;Company&rdquo;), a biopharmaceutical company focused on developing inflammation and
immunology (I&amp;I) biological products and providing CDMO services through its Scinai Bioservices business unit, announced that it has
entered into a Standby Equity Purchase Agreement (the &ldquo;SEPA&rdquo;) with YA II PN, Ltd. (&ldquo;Yorkville&rdquo;), a fund managed by
Yorkville Advisors Global, LP.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><IMG SRC="ex99-1_001.jpg" ALT="">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Under the terms of the SEPA, Scinai has&nbsp;the right, but not the
obligation,&nbsp;to sell up to $10 million (the &ldquo;Commitment Amount&rdquo;) of its American Depository Shares (&ldquo;ADSs&rdquo;), each
representing 4,000 ordinary shares, to Yorkville at any time during the three-year period following the execution date of the SEPA and
following the effectiveness of a registration statement filed with the Securities and Exchange Commission registering the ordinary shares
represented by the ADSs issuable pursuant to the SEPA. Sales to Yorkville under the SEPA are subject to a beneficial ownership cap of
9.99% of Scinai&rsquo;s share capital at any one time, along with other restrictions and conditions outlined in the SEPA.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The purchase price of the ADSs sold to Yorkville will be at a 3% discount
to the lowest daily volume-weighted average price of the ADSs during the three consecutive trading days commencing on the trading day
of the delivery&nbsp;of an advance notice&nbsp;by Scinai.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: normal 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scinai retains full control over the timing and amount of any sales
to Yorkville, with no obligation&nbsp;to utilize any of the $10 million available under the SEPA. Advances cannot be initiated by Yorkville,
and there are no minimum commitments or penalties for non-use. The SEPA imposes no restrictions on Scinai&rsquo;s operating activities or other
capital-raising efforts.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&ldquo;The SEPA provides us with significant flexibility to access additional
capital as we advance our R&amp;D programs, expand our CDMO business, and pursue strategic opportunities,&rdquo; said Amir Reichman, CEO
of Scinai. &ldquo;We believe the terms are highly favorable, allowing us to raise capital from time to time at our discretion at a minimal
discount to the then current market price without issuing warrants. By controlling the use and timing of the SEPA, we can capitalize on
favorable market conditions as they arise.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">The Company intends to use the proceeds from the potential offering
of ADSs under the SEPA to further develop its NanoAbs programs, support its CDMO business, and for general corporate purposes, including
working capital, research and development activities, regulatory matters, and capital investments.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">For a fuller description of the SEPA, see the Company&rsquo;s Form 6-K submitted
to the Securities and Exchange Commission on March 4, 2025.The securities described herein have not been registered under the Securities
Act of 1933, as amended, and may not be sold in the United States absent registration or an applicable exemption from the registration
requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any
sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or other jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>About Scinai Immunotherapeutics</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) is a biopharmaceutical
company with two complementary business units, one focused on in-house development of inflammation and immunology (I&amp;I) biological
therapeutic products beginning with an innovative, de-risked pipeline of nanosized VHH antibodies (nanoAbs) targeting diseases with large
unmet medical needs, and the other a boutique CDMO providing biological drug development, analytical methods development, clinical cGMP
manufacturing, and pre-clinical and clinical trial design and execution services for early stage biotech drug development projects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company website:&nbsp;www.scinai.com.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Company Contacts</B>&nbsp;Investor Relations | +972 8 930 2529 |&nbsp;ir@scinai.com<BR>
Business Development | +972 8 930 2529 |&nbsp;bd@scinai.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Forward-Looking Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release contains forward-looking statements within the meaning
of the Private Litigation Reform Act of 1995. Words such as &ldquo;expect,&rdquo; &ldquo;believe,&rdquo; &ldquo;intend,&rdquo; &ldquo;plan,&rdquo;
&ldquo;continue,&rdquo; &ldquo;may,&rdquo; &ldquo;will,&rdquo; &ldquo;anticipate,&rdquo; and similar expressions are intended to identify forward-looking
statements. All statements, other than statements of historical facts, are forward-looking statements.&nbsp;These forward-looking statements
reflect management&rsquo;s current views with respect to certain current and future events and are subject to various risks, uncertainties and
assumptions that could cause the results to differ materially from those expected by the management of Scinai Immunotherapeutics Ltd.
Risks and uncertainties include, but are not limited to;&nbsp; the risk that we won&rsquo;t raise any capital under SEPA or that we will not
otherwise benefit from the SEPA as currently anticipated; lower than anticipated revenues of Scinai&rsquo;s CDMO business; the risk that Scinai&rsquo;s
expanded presence in the U.S. will not significantly enhance the prospects of its CDMO unit; the risk that the Company will otherwise
be unable to&nbsp; remain compliant with the continued listing requirements of Nasdaq; failure to sign agreements with other potential
clients of the CDMO business; a delay in the commencement and results of pre-clinical and clinical studies, including the Phase 1/2a study
for psoriasis, the risk of delay in, Scinai&rsquo;s inability to conduct, or the unsuccessful results of, its research and development activities,
including the contemplated in-vivo studies and a clinical trial; the risk that Scinai will not be successful in expanding its CDMO business
or in-license other NanoAbs; the risk that Scinai may not be able to secure additional capital on attractive terms, if at all; the risk
that the therapeutic and commercial potential of NanoAbs will not be met or that Scinai will not be successful in bringing the NanoAbs
towards commercialization; the risk of a delay in the preclinical and clinical trials data for NanoAbs, if any; the risk that our business
strategy may not be successful; Scinai&rsquo;s ability to acquire rights to additional product opportunities; Scinai&rsquo;s ability to enter into
collaborations on terms acceptable to Scinai or at all; timing of receipt of regulatory approval of Scinai&rsquo;s manufacturing facility in
Jerusalem, if at all or when required; the risk that the manufacturing facility will not be able to be used for a wide variety of applications
and other vaccine and treatment technologies; and the risk that drug development involves a lengthy and expensive process with uncertain
outcomes. More detailed information about the risks and uncertainties affecting the Company is contained under the heading &ldquo;Risk
Factors&rdquo; in the Company&rsquo;s Annual Report on Form 20-F filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on May 15,
2024, and the Company&rsquo;s subsequent filings with the SEC. Scinai undertakes no obligation to revise or update any forward-looking statement
for any reason.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Logo:&nbsp;https://mma.prnewswire.com/media/2310190/Scinai_Immunotherapeutics_Logo.jpg</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 0pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 ex99-1_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &0 9 # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB3L=V"HJI)N6Q[E;7$=U;1SQ-F.10ZGV-35Q/P^U;[382Z=(V7MSN0'^X?\
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M,V2" C+_ +I'\C^=>IZ+KUAK]D+JQFW+T=&X9#Z,.U> :QI%_H-\UGJ$/ER
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MR!+#_KWC_P#015_O6?HG_("T_P#Z]H__ $$5H=ZS/+>["BBB@04444 %%%%
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MAX@US3Y(D2/3Y(DC92<OO3<<UF^./%EWX4CTZ6VM$N5GF9958G*QJNYBN.^
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M*** "BBB@ H-%% ')^'8)H_&/BN1XI$CDGMS&S*0'Q$.A[TSQ9:277B+PL!
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MW!NQ"GGXZ;\#=C\<U;H%%22%%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
2%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
